<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:06:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5637106" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5637106</identifier>
        <datestamp>2017-10-16</datestamp>
        <setSpec>bloodcancer</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="letter">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood Cancer J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood Cancer J</journal-id>
              <journal-title-group>
                <journal-title>Blood Cancer Journal</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-5385</issn>
              <publisher>
                <publisher-name>Nature Publishing Group</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5637106</article-id>
              <article-id pub-id-type="pmcid">PMC5637106</article-id>
              <article-id pub-id-type="pmc-uid">5637106</article-id>
              <article-id pub-id-type="pmid">29016571</article-id>
              <article-id pub-id-type="pii">bcj201776</article-id>
              <article-id pub-id-type="doi">10.1038/bcj.2017.76</article-id>
              <article-id pub-id-type="pmid">29016571</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Letter to the Editor</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Prevalence and timing of <italic>TP53</italic> mutations in del(17p) myeloma and effect on survival</article-title>
                <alt-title alt-title-type="running">Letter to the Editor</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chin</surname>
                    <given-names>M</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sive</surname>
                    <given-names>J I</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Allen</surname>
                    <given-names>C</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Roddie</surname>
                    <given-names>C</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chavda</surname>
                    <given-names>S J</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>D</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Blombery</surname>
                    <given-names>P</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>K</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ryland</surname>
                    <given-names>G L</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Popat</surname>
                    <given-names>R</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rismani</surname>
                    <given-names>A</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>D'Sa</surname>
                    <given-names>S</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rabin</surname>
                    <given-names>N</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gale</surname>
                    <given-names>R E</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yong</surname>
                    <given-names>K L</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="corresp" rid="caf1">*</xref>
                </contrib>
                <aff id="aff1"><label>1</label><institution>Department of Haematology, UCL Cancer Institute</institution>, London, <country>UK</country></aff>
                <aff id="aff2"><label>2</label><institution>Department of Haemato-Oncology, St Bartholomew's Hospital</institution>, London, <country>UK</country></aff>
                <aff id="aff3"><label>3</label><institution>Department of Pathology, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country>Australia</country></aff>
                <aff id="aff4"><label>4</label><institution>Department of Haematology, UCLH</institution>, London, <country>UK</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="caf1"><label>*</label>E-mail: <email>kwee.yong@ucl.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>09</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>15</day>
                <month>09</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>9</month>
                <year>2017</year>
              </pub-date>
              <volume>7</volume>
              <issue>9</issue>
              <fpage>e610</fpage>
              <lpage/>
              <permissions>
                <copyright-statement>Copyright © 2017 The Author(s)</copyright-statement>
                <copyright-year>2017</copyright-year>
                <copyright-holder>The Author(s)</copyright-holder>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <!--author-paid-->
                  <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
                </license>
              </permissions>
            </article-meta>
          </front>
          <body>
            <p>The recent remarkable advances in multiple myeloma (MM) therapy and outcomes have had mixed impact on patients with adverse risk genetics, many of whom continue to have inferior outcomes. This applies particularly to deletion of chromosome 17p13 [del(17p)], found in ≈10% of newly diagnosed MM (ND) and at higher prevalence in advanced disease.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref></sup> The <italic>TP53</italic> gene is located within the minimally deleted region on 17p13, and is thought to confer the adverse risk in a haploinsufficient manner.<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> The incidence of <italic>TP53</italic> mutations in ND is ≈3% but also increases with disease progression,<sup><xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref></sup> and is associated with shorter survival.<sup><xref ref-type="bibr" rid="bib9">9</xref></sup> Although <italic>TP53</italic> mutations are uncommon in the absence of del(17p), approximately one third of del(17p) MM patients are reported to have a <italic>TP53</italic> mutation, and this increases in refractory disease to more than 50%.<sup><xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib10">10</xref></sup></p>
            <p>The prognostic impact of <italic>TP53</italic> mutations in del(17p) MM remains unresolved.<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib10">10</xref></sup> We therefore carried out mutational analysis of a series of MM patients who had fluorescence <italic>in situ</italic> hybridization (FISH)-identified del(17p) to correlate with clinical outcomes.</p>
            <p>Ethical approval was obtained from National Research Ethics Service, London and informed consent in accordance with the Declaration of Helsinki. Out of 286 patients (2009–2014) tested at our centre using FISH on CD138+ bone marrow cells (Miltenyi microbead isolation), del(17p) was detected in 10 out of 98 (10.2%) ND and 42 out of 188 (22.3%) relapsed patients. An additional 6 patients were diagnosed with del(17p) at another centre. Material was available for all 16 ND and 35 relapse patients for mutational screening. In 23 patients, samples were available at more than one time point (range 2–4). FISH analysis was performed using standard probes.<sup><xref ref-type="bibr" rid="bib11">11</xref></sup> Genomic DNA was amplified by polymerase chain reaction and screened for <italic>TP53</italic> mutations in exons 4–11 using denaturing high-performance liquid chromatography (DHPLC; Transgenomic, Glasgow, UK). Mutations were verified by Sanger sequencing. Extended mutation testing was performed on <italic>TP53-</italic>mutated samples using targeted next generation sequencing (NGS; <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials</xref>). Clinical details including treatment and disease response (2014 IMWG criteria) were collated. Survival was estimated using Kaplan–Meier methods, and differences were assessed by log-rank test, with <italic>P</italic>-values &lt;0.05 considered statistically significant.</p>
            <p>Eighteen different <italic>TP53</italic> mutations were identified in 18 del(17p) patients (35%) by DHPLC (<xref rid="tbl1" ref-type="table">Table 1</xref>). Consistent with other studies,<sup><xref ref-type="bibr" rid="bib10">10</xref></sup> most mutations occurred in exons 5, 6 and 8 encoding an integral part of the p53 DNA binding domain. Seventeen (94%) were single-nucleotide variants (SNVs), a similar spectrum to that reported previously,<sup><xref ref-type="bibr" rid="bib10">10</xref></sup> although others have found deletions or insertions.<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> Seventeen SNVs were documented on the International Agency for Research on Cancer <italic>TP53</italic> database; 14 (82%) were missense mutations, two nonsense mutations and one altered a splice site. Most were predicted to produce a non-functional protein with &lt;20% transcriptional activity. The remaining mutation was a novel in-frame indel. In 83% of samples, the variant allele frequency of the <italic>TP53</italic> mutation was &gt;50%, consistent with the known del(17p) in a significant proportion of cells. In three patients, additional low-level <italic>TP53</italic> mutations were detected by NGS.</p>
            <p>Twenty-three patients were tested more than once, including 8 patients with <italic>TP53</italic> mutations, allowing us to explore the chronology of these genetic events. <italic>TP53</italic> mutations were identified at multiple time points in 5 patients (<xref rid="tbl1" ref-type="table">Table 1</xref>). In case 1, the mutant level increased with disease progression, indicating selection of the <italic>TP53</italic>-mutated clone. Case 11 showed clonal evolution with the appearance of a <italic>FAM46C</italic> mutation at relapse. Three patients (cases 3, 4 and 9) had consistently high mutant levels at both time points. The subclonal nonsense mutation detected in case 3 was only present in the first mutated sample. Thirteen of the 18 <italic>TP53</italic>-mutated patients (72%) were mutant-positive in the first sample analyzed (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). In five this was at diagnosis, indicating that 31% (5 of 16) of patients in this cohort presented with both del(17p) and a <italic>TP53</italic> mutation (cases 11, 15–18). However, this frequency may be an underestimate as diagnostic samples were not available from two patients who presented with del(17p), both of whom were <italic>TP53</italic>-mutated in a subsequent relapse sample (cases 5 and 10). In six patients, it was not possible to determine the chronology of their acquisition as earlier FISH results or stored samples were not available. In cases 1, 3 and 6, <italic>TP53</italic> mutations were only detected at relapse despite mutational testing in earlier samples. Two of these patients also only acquired the del(17p) at relapse. Of note, in both the remaining two patients (cases 2 and 7), del(17p) acquisition clearly preceded the <italic>TP53</italic> mutation. Case 2 acquired del(17p) at first relapse 34 months post-diagnosis but only acquired a <italic>TP53</italic> mutation at their fourth relapse 73 months post-diagnosis. Case 7 presented with del(17p), was mutant-negative at relapse 17 months later, but acquired a <italic>TP53</italic> mutation at second relapse 26 months post-diagnosis. The chronology of FISH and mutational testing for the 33 del(17p) patients without <italic>TP53</italic> mutations is shown in <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>.</p>
            <p>There was no difference in age at diagnosis or disease isotype between <italic>TP53</italic>-mutated and non-mutated patients (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>). Ten <italic>TP53-</italic>mutated patients (56%) also had at least one other high-risk cytogenetic feature detected at some point in their disease (t(4;14), t(14;16) or 1q gain; <xref rid="tbl1" ref-type="table">Table 1</xref>), but this frequency was not significantly different from the non-<italic>TP53-</italic>mutated patients (56 vs 49%, <italic>P</italic>=0.6). Ten <italic>TP53-</italic>mutated patients (56%) also had additional mutations in previously reported myeloma driver genes<sup><xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib12">12</xref></sup> [DIS3(5), FAM46C(3), NRAS(3), KRAS(2), TRAF3(2), FGFR3(1), PRDM1(1), ATM(1), BRAF(1) and PIK3CA(1)] and most of these patients (7, 39%) had two or more additional mutations (<xref rid="tbl1" ref-type="table">Table 1</xref>); in our series, the incidence of <italic>DIS3</italic> mutations (28%) appears higher.</p>
            <p>Median overall survival (OS) from diagnosis was significantly shorter in <italic>TP53</italic>-mutated than in non-mutated patients (19 vs 74 months, <italic>P</italic>=0.02; <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>), as was median OS from the time at which del(17p) was first detected (8 vs 29 months, <italic>P</italic>&lt;0.01; <xref ref-type="fig" rid="fig1">Figure 1b</xref>). Median progression-free survival (PFS) from first detection of del(17p) was similar between the two groups (7 vs 12 months, <italic>P</italic>=0.51; <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S3A</xref>), but the acquisition of a <italic>TP53</italic> mutation was associated with extremely poor survival. Median PFS of patients from the time a mutation was first detected was 5 months (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S3B</xref>), and median OS was 7 months (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). In contrast, patients who remained without detectable <italic>TP53</italic> mutation had a median PFS of 11.5 months, with median OS 17 months, calculated from the date of the last sample tested. There was thus a striking difference in survival between patients with and without <italic>TP53</italic> mutations. These results confirm that, although homozygous deletion of <italic>TP53</italic> in MM is uncommon,<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> inactivating <italic>TP53</italic> mutations that are likely to produce non-functional proteins are frequent in del(17p) MM. <italic>TP53</italic> haploinsufficiency in MM causes downstream p53 pathway deregulation, altering the delivery of an apoptotic response,<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> but the biological consequence of the additional functional loss conferred by mutation of the remaining allele remains unclear. In this cohort, we observed that <italic>TP53</italic> mutation usually occurred after, or simultaneously with, allelic loss of 17p13, and conferred a significantly poorer prognosis for those patients with both abnormalities. Bi-allelic inactivation of tumor suppressor genes, including <italic>TP53</italic>, has been reported to drive relapse in MM. A recent longitudinal study similarly identified that bi-allelic events leading to complete <italic>TP53</italic> inactivation resulted in the poorest prognosis at relapse.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> Patients with the lowest levels of <italic>TP53</italic> mRNA have also been reported to have the worst clinical outcome.<sup><xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup> There is also evidence of other mechanisms leading to p53 inactivation in MM, including promoter methylation<xref ref-type="bibr" rid="bib6"><sup>6</sup></xref> and aberrant expression and function of p53-regulating miRNAs,<sup><xref ref-type="bibr" rid="bib15">15</xref></sup> thus investigation of <italic>TP53</italic> mRNA and p53 protein levels may be warranted. Collectively our results confirm that, in the context of del(17p), acquisition of a <italic>TP53</italic> mutation on the other allele confers significantly worse clinical outcomes, and suggest that allelic loss of 17p13 likely precedes such mutations. In the era of genomic medicine, there is a case for routinely screening for <italic>TP53</italic> mutations in del(17p) MM to aid management decisions and direct these high-risk patients towards alternative treatment strategies aimed at counteracting the loss of tumor suppressor activity. Finally, the possibility of a different target gene for del(17p) in patients who do not have mutations of <italic>TP53</italic> remains to be explored.</p>
          </body>
          <back>
            <ack>
              <p>UCL/UCLH receives funding as an NIHR Biomedical Research Centre. We would like to acknowledge the generous support of The Snowdome Foundation.</p>
            </ack>
            <fn-group>
              <fn>
                <p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>The authors declare no conflict of interest.</p>
              </fn>
            </fn-group>
            <ref-list>
              <ref id="bib1">
                <mixed-citation publication-type="journal">Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Huilin C et al. <article-title>Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome</article-title>. <source>Blood</source>
<year>2007</year>; <volume>109</volume>: <fpage>3489</fpage>–3495.<pub-id pub-id-type="pmid">17209057</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <mixed-citation publication-type="journal">Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. <article-title>Clinical significance of <italic>TP53</italic> mutation in myeloma</article-title>. <source>Leukemia</source>
<year>2007</year>; <volume>21</volume>: <fpage>582</fpage>–584.<pub-id pub-id-type="pmid">17215851</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <mixed-citation publication-type="journal">Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ et al. <article-title>The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy</article-title>. <source>Genes Chromosomes Cancer</source>
<year>2011</year>; <volume>50</volume>: <fpage>765</fpage>–774.<pub-id pub-id-type="pmid">21961181</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <mixed-citation publication-type="journal">Fonseca R, Bergasel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. <article-title>The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy</article-title>. <source>Genes Chromosomes Cancer</source>
<year>2011</year>; <volume>50</volume>: <fpage>765</fpage>–774.<pub-id pub-id-type="pmid">21961181</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <mixed-citation publication-type="journal">Bergsagel PL, Mateos M-V, Gutierrez NC, Rajkumar SV, San Miguel JF. <article-title>Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma</article-title>. <source>Blood</source>
<year>2013</year>; <volume>121</volume>: <fpage>884</fpage>–892.<pub-id pub-id-type="pmid">23165477</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <mixed-citation publication-type="journal">Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB et al. <article-title>p53 haploinsufficiency and functional abnormalities in multiple myeloma</article-title>. <source>Leukemia</source>
<year>2014</year>; <volume>28</volume>: <fpage>2066</fpage>–2074.<pub-id pub-id-type="pmid">24625551</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <mixed-citation publication-type="journal">Lionetti M, Barbieri M, Manzoni M, Fabris S, Bandini C, Todoerti K et al. <article-title>Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature</article-title>. <source>Oncotarget</source>
<year>2016</year>; <volume>7</volume>: <fpage>21353</fpage>–21361.<pub-id pub-id-type="pmid">26870891</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <mixed-citation publication-type="journal">Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L et al. <article-title>Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes</article-title>. <source>Blood</source>
<year>2016</year>; <volume>128</volume>: <fpage>1226</fpage>–1233.<pub-id pub-id-type="pmid">27458004</pub-id></mixed-citation>
              </ref>
              <ref id="bib9">
                <mixed-citation publication-type="journal">Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM et al. <article-title>Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume>: <fpage>3911</fpage>–3920.<pub-id pub-id-type="pmid">26282654</pub-id></mixed-citation>
              </ref>
              <ref id="bib10">
                <mixed-citation publication-type="journal">Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S et al. <article-title>Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma</article-title>. <source>Haematologica</source>
<year>2010</year>; <volume>95</volume>: <fpage>1973</fpage>–1976.<pub-id pub-id-type="pmid">20634494</pub-id></mixed-citation>
              </ref>
              <ref id="bib11">
                <mixed-citation publication-type="journal">Smith D, Stephenson C, Percy L, Lach A, Chatters S, Kempski H et al. <article-title>Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy</article-title>. <source>Br J Haematol</source>
<year>2015</year>; <volume>171</volume>: <fpage>881</fpage>–883.<pub-id pub-id-type="pmid">25899469</pub-id></mixed-citation>
              </ref>
              <ref id="bib12">
                <mixed-citation publication-type="journal">Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX et al. <article-title>Targeted sequencing using a 47 gene multiple myeloma mutation panel (M<sup>3</sup>P) in -17p high risk disease</article-title>. <source>Br J Haematol</source>
<year>2015</year>; <volume>168</volume>: <fpage>507</fpage>–510.<pub-id pub-id-type="pmid">25302557</pub-id></mixed-citation>
              </ref>
              <ref id="bib13">
                <mixed-citation publication-type="journal">Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW et al. <article-title>Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma</article-title>. <source>Blood</source>
<year>2016</year>; <volume>128</volume>: <fpage>1735</fpage>–1744.<pub-id pub-id-type="pmid">27516441</pub-id></mixed-citation>
              </ref>
              <ref id="bib14">
                <mixed-citation publication-type="journal">Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S et al. <article-title>An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma</article-title>. <source>Blood</source>
<year>2008</year>; <volume>112</volume>: <fpage>4235</fpage>–4246.<pub-id pub-id-type="pmid">18337559</pub-id></mixed-citation>
              </ref>
              <ref id="bib15">
                <mixed-citation publication-type="journal">Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R et al. <article-title>Downregulation of p53-inducible microRNAs 192, 194 and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development</article-title>. <source>Cancer Cell</source>
<year>2010</year>; <volume>18</volume>: <fpage>367</fpage>–381.<pub-id pub-id-type="pmid">20951946</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <sec sec-type="supplementary-material" id="sup1">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="xob1">
                <label>Supplementary Materials</label>
                <media xlink:href="bcj201776x1.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </back>
          <floats-group>
            <fig id="fig1">
              <label>Figure 1</label>
              <caption>
                <p>Clinical impact of <italic>TP53</italic> mutations. (<bold>a</bold>) Swimmer plot displaying the time of del(17p) FISH testing/detection and <italic>TP53</italic> mutation screening for each <italic>TP53</italic>-mutated patient. Kaplan–Meier curves for (<bold>b</bold>) overall survival (OS) from first detection of del(17p) in patients with and without <italic>TP53</italic> mutations, and (<bold>c</bold>) from first detection of the mutation in <italic>TP53-</italic>mutated patients compared to the last time point tested in non-mutated patients. Dotted Line, <italic>TP53-</italic>mutated patients; solid line, non-<italic>TP53</italic> patients. CI, 95% confidence intervals; HR, hazard ratios.</p>
              </caption>
              <graphic xlink:href="bcj201776f1"/>
            </fig>
            <table-wrap id="tbl1">
              <label>Table 1</label>
              <caption>
                <title>Summary of TP53 mutations identified in the cohort</title>
              </caption>
              <table frame="hsides" rules="groups" border="1">
                <colgroup>
                  <col align="left"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                </colgroup>
                <thead valign="bottom">
                  <tr>
                    <th align="left" valign="top" charoff="50">
                      <italic>ID</italic>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>Disease status at time of mutation detection</italic>
                    </th>
                    <th align="center" valign="top" charoff="50">
                      <italic>Months since diagnosis</italic>
                    </th>
                    <th align="center" valign="top" charoff="50">
                      <italic>Del(17p) % by FISH</italic>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>Mutated TP53 exon</italic>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>TP53 mutation</italic>
                    </th>
                    <th align="center" valign="top" charoff="50">
                      <italic>TP53 mutation VAF (%)</italic>
                      <xref ref-type="fn" rid="t1-fn2">a</xref>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>On IARC TP53</italic>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>Mutational effect</italic>
                      <xref ref-type="fn" rid="t1-fn3">b</xref>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>Additional mutations</italic>
                      <xref ref-type="fn" rid="t1-fn4">c</xref>
                    </th>
                    <th align="left" valign="top" charoff="50">
                      <italic>Additional FISH abnormalities</italic>
                    </th>
                  </tr>
                </thead>
                <tbody valign="top">
                  <tr>
                    <td align="left" valign="top" charoff="50">1<xref ref-type="fn" rid="t1-fn5">d</xref></td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">178</td>
                    <td align="center" valign="top" charoff="50">100</td>
                    <td align="left" valign="top" charoff="50">7</td>
                    <td align="left" valign="top" charoff="50">p.C242S</td>
                    <td align="center" valign="top" charoff="50">52</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">DIS3 (14%), TRAF3 (1%)</td>
                    <td align="left" valign="top" charoff="50">t(4;14)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50"> </td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">184</td>
                    <td align="center" valign="top" charoff="50">74</td>
                    <td align="left" valign="top" charoff="50">7</td>
                    <td align="left" valign="top" charoff="50">p.C242S</td>
                    <td align="center" valign="top" charoff="50">90</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">DIS3 (4%), TRAF3 (13%)</td>
                    <td align="left" valign="top" charoff="50">t(4;14), 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">2</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">73</td>
                    <td align="center" valign="top" charoff="50">78</td>
                    <td align="left" valign="top" charoff="50">6</td>
                    <td align="left" valign="top" charoff="50">p.P190L</td>
                    <td align="center" valign="top" charoff="50">12</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Partially functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">None</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">3<xref ref-type="fn" rid="t1-fn5">d</xref></td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">75</td>
                    <td align="center" valign="top" charoff="50">53</td>
                    <td align="left" valign="top" charoff="50">Int/Ex 9
10</td>
                    <td align="left" valign="top" charoff="50">c.993+2T&gt;C
p.R342X<xref ref-type="fn" rid="t1-fn6">e</xref></td>
                    <td align="center" valign="top" charoff="50">90
12</td>
                    <td align="left" valign="top" charoff="50">Yes
Yes</td>
                    <td align="left" valign="top" charoff="50">Disrupt splicing
Nonsense</td>
                    <td align="left" valign="top" charoff="50">DIS3 (88%), FGFR3 (36%)</td>
                    <td align="left" valign="top" charoff="50">t(4;14), 1q+, 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50"> </td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">86</td>
                    <td align="center" valign="top" charoff="50">87</td>
                    <td align="left" valign="top" charoff="50">Int/Ex 9</td>
                    <td align="left" valign="top" charoff="50">c.993+2T&gt;C</td>
                    <td align="center" valign="top" charoff="50">97</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Disrupt splicing</td>
                    <td align="left" valign="top" charoff="50">DIS3 (99%), FGFR3 (45%)</td>
                    <td align="left" valign="top" charoff="50">t(4;14), 1q+,1p-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">4<xref ref-type="fn" rid="t1-fn5">d</xref></td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">56</td>
                    <td align="center" valign="top" charoff="50">99</td>
                    <td align="left" valign="top" charoff="50">6</td>
                    <td align="left" valign="top" charoff="50">p.I195T</td>
                    <td align="center" valign="top" charoff="50">97</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">KRAS (48%), FAM46C (31%)</td>
                    <td align="left" valign="top" charoff="50">1q+, 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50"> </td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">79</td>
                    <td align="center" valign="top" charoff="50">99</td>
                    <td align="left" valign="top" charoff="50">6</td>
                    <td align="left" valign="top" charoff="50">p.I195T</td>
                    <td align="center" valign="top" charoff="50">93</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">KRAS (47%), FAM46C (16%)</td>
                    <td align="left" valign="top" charoff="50">1q+, 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">5</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">46</td>
                    <td align="center" valign="top" charoff="50">79</td>
                    <td align="left" valign="top" charoff="50">5</td>
                    <td align="left" valign="top" charoff="50">p.C141Y</td>
                    <td align="center" valign="top" charoff="50">66</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">None</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">6</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">63</td>
                    <td align="center" valign="top" charoff="50">33</td>
                    <td align="left" valign="top" charoff="50">6</td>
                    <td align="left" valign="top" charoff="50">p.H193R</td>
                    <td align="center" valign="top" charoff="50">32</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional nonsense</td>
                    <td align="left" valign="top" charoff="50">NRAS (45%), DIS3 (41%)</td>
                    <td align="left" valign="top" charoff="50">Hyperdiploid</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">7</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">26</td>
                    <td align="center" valign="top" charoff="50">86</td>
                    <td align="left" valign="top" charoff="50">8
6</td>
                    <td align="left" valign="top" charoff="50">p.R267W
p.H214R<xref ref-type="fn" rid="t1-fn6">e</xref></td>
                    <td align="center" valign="top" charoff="50">64
11</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense
Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">1q+</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">8</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">26</td>
                    <td align="center" valign="top" charoff="50">100</td>
                    <td align="left" valign="top" charoff="50">5
9</td>
                    <td align="left" valign="top" charoff="50">p.A138_T140delinsTSGDRPA
p.Q317X<xref ref-type="fn" rid="t1-fn6">e</xref></td>
                    <td align="center" valign="top" charoff="50">78
9</td>
                    <td align="left" valign="top" charoff="50">No
Yes</td>
                    <td align="left" valign="top" charoff="50">In-frame indel
Nonsense</td>
                    <td align="left" valign="top" charoff="50">ATM (27%), DIS3 (34%), 
2x NRAS (9%) (12%)</td>
                    <td align="left" valign="top" charoff="50">1q+</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">9<xref ref-type="fn" rid="t1-fn5">d</xref></td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">14</td>
                    <td align="center" valign="top" charoff="50">80</td>
                    <td align="left" valign="top" charoff="50">7</td>
                    <td align="left" valign="top" charoff="50">p.Y234C</td>
                    <td align="center" valign="top" charoff="50">99</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">KRAS (43%)</td>
                    <td align="left" valign="top" charoff="50">1p-, 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50"> </td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">19</td>
                    <td align="center" valign="top" charoff="50">80</td>
                    <td align="left" valign="top" charoff="50">7</td>
                    <td align="left" valign="top" charoff="50">p.Y234C</td>
                    <td align="center" valign="top" charoff="50">80</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">KRAS (38%)</td>
                    <td align="left" valign="top" charoff="50">1p-, 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">10</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">12</td>
                    <td align="center" valign="top" charoff="50">100</td>
                    <td align="left" valign="top" charoff="50">8</td>
                    <td align="left" valign="top" charoff="50">p.E268A</td>
                    <td align="center" valign="top" charoff="50">97</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">None</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">11<xref ref-type="fn" rid="t1-fn5">d</xref></td>
                    <td align="left" valign="top" charoff="50">NDMM</td>
                    <td align="center" valign="top" charoff="50">0</td>
                    <td align="center" valign="top" charoff="50">100</td>
                    <td align="left" valign="top" charoff="50">10</td>
                    <td align="left" valign="top" charoff="50">p.L348S</td>
                    <td align="center" valign="top" charoff="50">67</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">PRDM1 (65%), DIS3 (11%)</td>
                    <td align="left" valign="top" charoff="50">13q-, t(4;14), 
1p-,Tetraploid</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50"> </td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">8</td>
                    <td align="center" valign="top" charoff="50">86</td>
                    <td align="left" valign="top" charoff="50">10</td>
                    <td align="left" valign="top" charoff="50">p.L348S</td>
                    <td align="center" valign="top" charoff="50">39</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">PRDM1 (38%), DIS3 (24%), FAM46C (32%)</td>
                    <td align="left" valign="top" charoff="50">13q-, t(4;14), 
1p-, Tetraploid</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">12</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">11</td>
                    <td align="center" valign="top" charoff="50">91</td>
                    <td align="left" valign="top" charoff="50">5</td>
                    <td align="left" valign="top" charoff="50">p.A161T</td>
                    <td align="center" valign="top" charoff="50">97</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Partially functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">t(14;16), 1q+</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">13</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">12</td>
                    <td align="center" valign="top" charoff="50">100</td>
                    <td align="left" valign="top" charoff="50">8</td>
                    <td align="left" valign="top" charoff="50">p.G279E</td>
                    <td align="center" valign="top" charoff="50">68</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">BRAF (30%)</td>
                    <td align="left" valign="top" charoff="50">1q+</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">14</td>
                    <td align="left" valign="top" charoff="50">Relapse</td>
                    <td align="center" valign="top" charoff="50">10</td>
                    <td align="center" valign="top" charoff="50">100</td>
                    <td align="left" valign="top" charoff="50">8</td>
                    <td align="left" valign="top" charoff="50">p.P278S</td>
                    <td align="center" valign="top" charoff="50">73</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">FAM46C (23%)</td>
                    <td align="left" valign="top" charoff="50">None</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">15</td>
                    <td align="left" valign="top" charoff="50">NDMM</td>
                    <td align="center" valign="top" charoff="50">0</td>
                    <td align="center" valign="top" charoff="50">84</td>
                    <td align="left" valign="top" charoff="50">6</td>
                    <td align="left" valign="top" charoff="50">p.Q192X</td>
                    <td align="center" valign="top" charoff="50">88</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Missense</td>
                    <td align="left" valign="top" charoff="50">NRAS (36%), PIK3CA (41%), TRAF3 (45%)</td>
                    <td align="left" valign="top" charoff="50">t(14;16), 13q-</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">16</td>
                    <td align="left" valign="top" charoff="50">NDMM</td>
                    <td align="center" valign="top" charoff="50">0</td>
                    <td align="center" valign="top" charoff="50">96</td>
                    <td align="left" valign="top" charoff="50">4</td>
                    <td align="left" valign="top" charoff="50">p.E62X</td>
                    <td align="center" valign="top" charoff="50">91</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Nonsense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">None</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">17</td>
                    <td align="left" valign="top" charoff="50">NDMM</td>
                    <td align="center" valign="top" charoff="50">0</td>
                    <td align="center" valign="top" charoff="50">92</td>
                    <td align="left" valign="top" charoff="50">5</td>
                    <td align="left" valign="top" charoff="50">p.V172D</td>
                    <td align="center" valign="top" charoff="50">98</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">t(11;14)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">18</td>
                    <td align="left" valign="top" charoff="50">NDMM</td>
                    <td align="center" valign="top" charoff="50">0</td>
                    <td align="center" valign="top" charoff="50">77</td>
                    <td align="left" valign="top" charoff="50">4</td>
                    <td align="left" valign="top" charoff="50">p.F109V</td>
                    <td align="center" valign="top" charoff="50">47</td>
                    <td align="left" valign="top" charoff="50">Yes</td>
                    <td align="left" valign="top" charoff="50">Non-functional missense</td>
                    <td align="left" valign="top" charoff="50">None</td>
                    <td align="left" valign="top" charoff="50">t(14;16), 1q+</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="t1-fn1">
                  <p>Abbreviations: FISH, fluorescence <italic>in situ</italic> hybridization; Int/Ex, intron/exon boundary; NDMM, newly diagnosed multiple myeloma; NGS, next generation sequencing; VAF, variant allele frequency.</p>
                </fn>
                <fn id="t1-fn2">
                  <label>a</label>
                  <p>VAF as determined by targeted NGS.</p>
                </fn>
                <fn id="t1-fn3">
                  <label>b</label>
                  <p>Taken from the International Agency for Research on Cancer (IARC) TP53 database; proteins with &lt;20% transcriptional activity were predicted to be non-functional and with 20–75% transcriptional activity partially functional.</p>
                </fn>
                <fn id="t1-fn4">
                  <label>c</label>
                  <p>Details are provided in <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S3</xref>.</p>
                </fn>
                <fn id="t1-fn5">
                  <label>d</label>
                  <p>Patients with longitudinal samples.</p>
                </fn>
                <fn id="t1-fn6">
                  <label>e</label>
                  <p>Mutation only detected by targeted NGS.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
